Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

JRNYS vs TeleCareSpot

JRNYS
Graded #267

Lower grade

vs+5.200000000000003
TeleCareSpot
Graded #160

Higher grade

The verdict

TeleCareSpot takes it — 67.7/100 to 62.5/100.

TeleCareSpot grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TeleCareSpot is a telehealth weight-loss platform offering doctor-prescribed compounded GLP-1s with flat, all-inclusive monthly pricing: compounded semaglutide at $299/month and tirzepatide at $399/month…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueJRNYS +2
45
43
Dose & formulationTeleCareSpot +25
58
83
Clinical oversightJRNYS +1
84
83
Labs & monitoringJRNYS +19
71
52
FulfillmentTeleCareSpot +27
65
92
Contract termsTeleCareSpot +6
55
61
JRNYS · left barTeleCareSpot · right bar

The numbers

MetricJRNYSTeleCareSpot
WeighScore62.5/10067.7/100
GradeCC
Scorecard rank#267#160
SemaglutideNot disclosed$299/mo (all doses, plus a separate fee, compounded)
TirzepatideNot disclosed$399/mo
CoverageCoverage not published48 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
JRNYS

Graded #267 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published
TeleCareSpot

Graded #160 · C

Strengths

  • Flat, all-inclusive monthly pricing with no hidden fees — compounded semaglutide $299/month and tirzepatide $399/month, all doses included
  • Verifiable LegitScript certification (seal ID 45936855) plus HIPAA compliance and licensed US physicians
  • Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
  • DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
  • Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Not available in Alaska, Mississippi, or New Jersey
  • The compounding pharmacy partner is not named
  • A separate weight-loss consultation fee applies (credited toward your medication package if approved)
  • Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard